Aurora Cannabis Secures EU Rights for Proprietary Varieties, Strengthening Global Market Position

Aurora Cannabis Strengthens Global Position with EU Plant Variety Rights

Aurora Cannabis Inc., a leading player in the medical cannabis industry, achieves a significant milestone by securing community plant variety rights from the EU's Community Plant Variety Office for two proprietary cannabis varieties. The varieties, known as Farm Gas™ (SOT20R07-007) and Sourdough™ (ACB21T044), reflect Aurora's commitment to innovation and excellence in cannabis genetics. Developed through advanced breeding and phenotyping programs in Canada, these cultivars are characterized by their high potency, appealing aromas, and robust bud structures. They have garnered popularity among medical patients in several countries, including Germany, Poland, the UK, Canada, and Australia.

The recognition from the EU reinforces the superior quality of cannabis genetics being developed at Aurora’s Coast R&D facility. Lana Culley, Aurora's Vice President of Innovation and International Operations, articulates that this accolade not only highlights the company’s genetic advancements but also solidifies its position as a leader in the global cannabis market. With the grant of exclusive rights for the commercial production and sale of these varieties across the EU's 27 member states, Aurora is poised to leverage its investments in scientific innovation more effectively. This strategic move strengthens the company’s ability to offer premium cannabis products tailored to the needs of medical patients.

The advantages of this achievement extend beyond immediate recognition; they place Aurora in a competitive position within the rapidly evolving European market for medical cannabis. The company’s robust genetics platform is fundamental to its leadership in the medical sector, ensuring the delivery of consistent and high-quality products. With existing rights in Canada and potential for expansion in other territories, Aurora's ability to commercialize its cultivars globally enhances both patient access to high-quality cannabis and the company's overall market presence.

In addition to the EU recognition, Aurora's advancements in cannabis genetics underscore a broader trend in the industry toward scientific rigor and product differentiation. As the market for medical cannabis continues to mature, such innovations will be crucial for companies aiming to meet the diverse needs of patients and healthcare providers.

Overall, Aurora Cannabis's recent developments highlight its commitment to pioneering high-quality cannabis genetics while enhancing patient access worldwide, reinforcing its status as a formidable entity in the cannabis sector.